Endocrine oncology

Patient-Reported Outcomes Three Years After Deciding on Surgery or Active Surveillance for Small, Low-Risk Papillary Thyroid Cancer: Results of a Prospective Cohort Study

ThyroidPublished Prospective cohort study

Authors' conclusion

We observed that PROs do not significantly differ between patients who chose AS and those who chose immediate surgery a few years after the initial disease management choice. However, patients who crossover from AS to surgery may experience greater cancer-related worry and decision regret.

Study context

Population
Canadian patients with small (<2 cm), low-risk papillary thyroid cancer (PTC) given the choice of active surveillance (AS) or immediate surgeryresponse rate 64% (120/188)
Participants
120 patients
Exposure
AS vs immediate surgery
  • ASn = 98
  • Immediate surgeryn = 22reference
Outcome
Patient-reported outcomes (PROs): overall and subscale scores of EORTC QLQ-C30, EORTC THY-34, Assessment of Survivor Concerns, Decision Regret Scale, GAD-7
Follow-up
Approximately three years after the initial disease management choice

Main finding

As reported in the abstract

PRO overall and subscale scores · median follow-up 42 months (IQR 39, 46)
  • No significant differences in overall scores or subscales of any questionnaire between AS and immediate surgery
  • After adjustment for multiple comparisons

Observational data: associations, not effects.

Further findings

Crossover from AS to surgery vs remained under AS and initial surgery

Greater cancer-related worry with crossover
P = 0.021
Greater overall worry with crossover
P = 0.021
Greater decision regret with crossover
P = 0.031
  • Secondary analysis

Original publication

Patient-Reported Outcomes Three Years After Deciding on Surgery or Active Surveillance for Small, Low-Risk Papillary Thyroid Cancer: Results of a Prospective Cohort Study. Thyroid. Published 12 March 2026. doi:10.1177/10507256251408857

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.